Tumor-associated neutrophils activated by tumor-derived CCL20 (C-C motif chemokine ligand 20) promote T cell immunosuppression via programmed death-ligand 1 (PD-L1) in breast cancer

References

• Azamjah N, Soltan-Zadeh Y, Zayeri F. Global trend of breast cancer mortality rate: a 25-year study. Asian Pac J Cancer Prev. 2019;20(7):2015–2020.
   PubMedGoogle Scholar
• Itani N, Grogan N, Mott S, et al. Metastatic presentations of previously treated early-stage breast cancer patients and association with survival. Clin Breast Cancer. 2020;20(3):209–214.
   PubMed Web of Science ®Google Scholar
• Skuli SJ, Sheng JY, Bantug ET, et al. Survivorship care visits in a high-risk population of breast cancer survivors. Breast Cancer Res Treat. 2019;173(3):701–708.
   PubMed Web of Science ®Google Scholar
• Susini T, Saccardin G, Renda I, et al. Immunohistochemical evaluation of FGD3 expression: a new strong prognostic factor in invasive breast cancer. Cancers (Basel). 2021;13(15):3824.
   PubMed Web of Science ®Google Scholar
• Ding L, Zhang Z, Xu Y, et al. Comparative study of Her-2, p53, Ki-67 expression and clinicopathological characteristics of breast cancer in a cohort of northern China female patients. Bioengineered. 2017;8(4):383–392.
   PubMed Web of Science ®Google Scholar
• Tan S, Xia L, Yi P, et al. Exosomal miRNAs in tumor microenvironment. J Exp Clin Cancer Res. 2020;39(1):67.
   PubMed Web of Science ®Google Scholar
• Roma-Rodrigues C, Mendes R, Baptista PV, et al. Targeting tumor microenvironment for cancer therapy. Int J Mol Sci. 2019;20(4):840.
   PubMed Web of Science ®Google Scholar
• Quail DF, Joyce JA. Microenvironmental regulation of tumor progression and metastasis. Nat Med. 2013;19(11):1423–1437.
   PubMed Web of Science ®Google Scholar
• Arneth B. Tumor microenvironment. Medicina (Kaunas). 2019;56(1):15.
   PubMed Web of Science ®Google Scholar
• Wu L, Saxena S, Awaji M, et al. Tumor-associated neutrophils in cancer: going pro. Cancers (Basel). 2019;11(4):564.
   PubMed Web of Science ®Google Scholar
• Germann M, Zangger N, Sauvain MO, et al. Neutrophils suppress tumor-infiltrating T cells in colon cancer via matrix metalloproteinase-mediated activation of TGFβ. EMBO Mol Med. 2020;12(1):e10681.
   PubMed Web of Science ®Google Scholar
• Sun B, Qin W, Song M, et al. Neutrophil suppresses tumor cell proliferation via fas /fas ligand pathway mediated cell cycle arrested. Int J Biol Sci. 2018;14(14):2103–2113.
   PubMed Web of Science ®Google Scholar
• Eruslanov EB, Bhojnagarwala PS, Quatromoni JG, et al. Tumor-associated neutrophils stimulate T cell responses in early-stage human lung cancer. J Clin Invest. 2014;124(12):5466–5480.
   PubMed Web of Science ®Google Scholar
• Cai Z, Zhang M, Boafo Kwantwi L, Bi X, Zhang C, Cheng Z, Ding X, Su T, Wang H, Wu Q. Breast cancer cells promote self-migration by secreting interleukin 8 to induce NET formation. Gene. 2020;754:144902.
   PubMed Web of Science ®Google Scholar
• Hajizadeh F, Aghebati Maleki L, Alexander M, et al. Tumor-associated neutrophils as new players in immunosuppressive process of the tumor microenvironment in breast cancer. Life Sci. 2021;264:118699.
   PubMed Web of Science ®Google Scholar
• Wang T-T, Zhao Y-L, Peng L-S, et al. Tumour-activated neutrophils in gastric cancer foster immune suppression and disease progression through GM-CSF-PD-L1 pathway. Gut. 2017;66(11):1900.
   PubMed Web of Science ®Google Scholar
• Shang A, Wang W, Gu C, et al. Long non-coding RNA HOTTIP enhances IL-6 expression to potentiate immune escape of ovarian cancer cells by upregulating the expression of PD-L1 in neutrophils. J Exp Clin Cancer Res. 2019;38(1):411.
   PubMed Web of Science ®Google Scholar
• Hippe A, Braun SA, Oláh P, et al. EGFR/Ras-induced CCL20 production modulates the tumour microenvironment. Br J Cancer. 2020;123(6):942–954.
   PubMed Web of Science ®Google Scholar
• Kadomoto S, Izumi K, Hiratsuka K, et al. Tumor-associated macrophages induce migration of renal cell carcinoma cells via Activation of the CCL20-CCR6 axis. Cancers (Basel). 2020;12(1):89.
   Web of Science ®Google Scholar
• Li Y, Liu J, Xiao Q, et al. EN2 as an oncogene promotes tumor progression via regulating CCL20 in colorectal cancer. Cell Death Dis. 2020;11(7):604.
   PubMed Web of Science ®Google Scholar
• Geismann C, Grohmann F, Dreher A, et al. Role of CCL20 mediated immune cell recruitment in NF-κB mediated TRAIL resistance of pancreatic cancer. Biochim Biophys Acta, Mol Cell Res. 2017;1864(5):782–796.
   PubMed Web of Science ®Google Scholar
• Wu -H-H, Hwang-Verslues WW, Lee W-H, et al. Targeting IL-17B–IL-17RB signaling with an anti–IL-17RB antibody blocks pancreatic cancer metastasis by silencing multiple chemokines. J Exp Med. 2015;212(3):333–349.
   PubMed Web of Science ®Google Scholar
• Yang B, Wang F, Zheng G. Transmembrane protein TMEM119 facilitates the stemness of breast cancer cells by activating Wnt/β-catenin pathway. Bioengineered. 2021;12(1):4856–4867.
   PubMed Web of Science ®Google Scholar
• Lei L, Tang L. Schwann cells genetically modified to express S100A4 increases GAP43 expression in spiral ganglion neurons in vitro. Bioengineered. 2017;8(4):404–410.
   PubMed Web of Science ®Google Scholar
• Shang D, Liu Y, Zhang J, et al. Peroxisome proliferator-activated receptor γ (PPARγ) suppresses the proliferation and metastasis of patients with urothelial carcinoma after renal transplantation by inhibiting LEF1/β-catenin signaling. Bioengineered. 2020;11(1):1350–1367.
   PubMed Web of Science ®Google Scholar
• Yamada Y, Nakagawa T, Sugihara T, et al. Prognostic value of CD66b positive tumor-infiltrating neutrophils in testicular germ cell tumor. BMC Cancer. 2016;16(1):898.
   PubMedGoogle Scholar
• Emens LA, Cruz C, Eder JP, et al. Long-term clinical outcomes and biomarker analyses of atezolizumab therapy for patients with metastatic triple-negative breast cancer: a phase 1 study. JAMA Oncol. 2019;5(1):74–82.
   PubMed Web of Science ®Google Scholar
• Li S, Cong X, Gao H, et al. Tumor-associated neutrophils induce EMT by IL-17a to promote migration and invasion in gastric cancer cells. J Exp Clin Cancer Res. 2019;38(1):6.
   PubMedGoogle Scholar
• Lianyuan T, Gang L, Ming T, et al. Tumor associated neutrophils promote the metastasis of pancreatic ductal adenocarcinoma. Cancer Biol Ther. 2020;21(10):937–945.
   PubMed Web of Science ®Google Scholar
• Comen E, Wojnarowicz P, Seshan VE, et al. TNF is a key cytokine mediating neutrophil cytotoxic activity in breast cancer patients. Npj Breast Cancer. 2016;2(1):16009.
   PubMedGoogle Scholar
• Li L, Yang C, Zhao Z, et al. Skewed T-helper (Th)1/2- and Th17/T regulatory‑cell balances in patients with renal cell carcinoma. Mol Med Rep. 2015;11(2):947–953.
   PubMed Web of Science ®Google Scholar
• Rao HL, Chen JW, Li M, et al. Increased intratumoral neutrophil in colorectal carcinomas correlates closely with malignant phenotype and predicts patients’ adverse prognosis. PloS One. 2012;7(1):e30806.
   PubMed Web of Science ®Google Scholar
• Carus A, Ladekarl M, Hager H, et al. Tumour-associated CD66b+ neutrophil count is an independent prognostic factor for recurrence in localised cervical cancer. Br J Cancer. 2013;108(10):2116–2122.
   PubMed Web of Science ®Google Scholar
• Bowers NL, Helton ES, Huijbregts RPH, et al. Immune suppression by neutrophils in HIV-1 infection: role of PD-L1/PD-1 pathway. PLoS Pathog. 2014;10(3):e1003993. e1003993-e1003993.
   PubMed Web of Science ®Google Scholar
• Cheng Y, Li H, Deng Y, et al. Cancer-associated fibroblasts induce PDL1+ neutrophils through the IL6-STAT3 pathway that foster immune suppression in hepatocellular carcinoma. Cell Death Dis. 2018;9(4):422.
   PubMed Web of Science ®Google Scholar
• Shi Y, Zhang J, Mao Z, et al. Extracellular vesicles from gastric cancer cells induce pd-l1 expression on neutrophils to suppress t-cell immunity. Front Oncol. 2020;10:629.
   PubMed Web of Science ®Google Scholar
• Sun R, Xiong Y, Liu H, et al. Tumor-associated neutrophils suppress antitumor immunity of NK cells through the PD-L1/PD-1 axis. Transl Oncol. 2020;13(10):100825.
   PubMed Web of Science ®Google Scholar
• Zheng Y, Fang YC, Li J. PD‑L1 expression levels on tumor cells affect their immunosuppressive activity. Oncol Lett. 2019;18(5):5399–5407.
   PubMed Web of Science ®Google Scholar
• He G, Zhang H, Zhou J, et al. Peritumoural neutrophils negatively regulate adaptive immunity via the PD-L1/PD-1 signalling pathway in hepatocellular carcinoma. J Exp Clin Cancer Res. 2015;34(1):141.
   PubMedGoogle Scholar
• Kowanetz M, Zou W, Gettinger SN, et al. Differential regulation of PD-L1 expression by immune and tumor cells in NSCLC and the response to treatment with atezolizumab (anti-PD-L1). Proc Natl Acad Sci U S A. 2018;115(43):E10119–E10126. E10119-E10126.
   PubMed Web of Science ®Google Scholar